home / stock / indp / indp news

INDP News and Press, Indaptus Therapeutics Inc. From 03/13/23

Stock Information
Company Name: Indaptus Therapeutics Inc.
Stock Symbol: INDP
Market: NASDAQ
Website: indaptusrx.com/
Menu
INDP INDP Quote INDP Short INDP News INDP Articles INDP Message Board
Get INDP Alerts

News, Short Squeeze, Breakout and More Instantly...
INDP - Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that Atlanta, Ga.-based Emory W...
INDP - Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the dosing of the first subject...

INDP - Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has named Robert Martell, M.D...

INDP - Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the addition of Morristown Medic...
INDP - Indaptus stock rises on start of phase 1 trial of cancer drug Decoy20

Indaptus Therapeutics ( NASDAQ: INDP ) said it started phase 1 trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors. The USC Norris Cancer Center in Los Angeles is the first activated clinical trial site which has been opened for enrollment, and pat...

INDP - Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the initiation of INDP-D101, its...

INDP - Indaptus Therapeutics GAAP EPS of -$0.42 beats by $0.09

Indaptus Therapeutics press release ( NASDAQ: INDP ): Q3 GAAP EPS of -$0.42 beats by $0.09 . As of September 30, 2022, the company had cash, cash equivalents and marketable securities of approximately $28.5 million. As of December 31, 2021, the Company had cash and...
INDP - Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Company Remain s On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022 NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today anno...

INDP - Indaptus Therapeutics to Present at the LD Micro Main Event XV

NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the LD Micro Main Event XV. The conference is being held on October 25 – 27, 2022 at the Luxe S...

INDP - Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the 24 th Annual H.C. Wainwright Global Investment Conference. The conference is being held on Se...
Previous 10 Next 10